For adult patients with type 2 diabetes
Levemir® once dailya added to metformin + Victoza® (liraglutide [rDNA origin] injection) helped achieve treatment goals1,b
Significant reductions in A1C and FPG over 26 weeks1
- Main treatment period lasted 26 weeks
- Patients with A1C ≥7% were randomized 1:1 to either
- Metformin + Victoza® 1.8 mg (n=161)
- Metformin + Victoza® 1.8 mg + Levemir® starting at 10 units/day (n=162)
This was a multinational, open-label study of 988 insulin-naïve adults with type 2 diabetes (18 to 80 years) who were uncontrolled on metformin ≥1500 mg/day +/– SU. All patients underwent a 12-week run-in with metformin and Victoza® once daily, titrated to 1.8 mg. At the end of the run-in period, if patients achieved A1C <7%, they continued treatment in a nonrandomized, observational arm (50% of patients from run-in). If A1C was ≥7% at the end of run-in, patients were randomized to 26 weeks of once-daily Levemir® as add-on therapy or to continued, unchanged treatment with Victoza® 1.8 mg and metformin.2
aLevemir® can be dosed once or twice daily.
bVictoza® is a GLP-1 receptor agonist.
In the metformin + Victoza® + Levemir® arm1,2,c
cP<0.0001 was vs metformin + Victoza® group. Results from the metformin + Victoza® arm not shown.
- 43% of patients in the metformin + Victoza® + Levemir® arm reached goal of A1C<7%1,2